A phase I study to determine the safety and pharmacokinetics of BMS-387032 [SNS 032] given every three weeks in patients with metastatic refractory solid tumors-C

Trial Profile

A phase I study to determine the safety and pharmacokinetics of BMS-387032 [SNS 032] given every three weeks in patients with metastatic refractory solid tumors-C

Not stated
Phase of Trial: Phase I

Latest Information Update: 29 Jun 2007

At a glance

  • Drugs SNS 032 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 29 Jun 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top